Cited 29 times in
Outcome of adjuvant therapy for gallbladder cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박준성 | - |
dc.contributor.author | 송시영 | - |
dc.contributor.author | 윤동섭 | - |
dc.contributor.author | 이동기 | - |
dc.contributor.author | 이세준 | - |
dc.contributor.author | 이우정 | - |
dc.contributor.author | 임재윤 | - |
dc.contributor.author | 조재용 | - |
dc.contributor.author | 최혜진 | - |
dc.date.accessioned | 2015-04-23T17:34:10Z | - |
dc.date.available | 2015-04-23T17:34:10Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/102718 | - |
dc.description.abstract | OBJECTIVES: The aim of this study was to evaluate the outcome of adjuvant therapy on the overall survival (OS) and disease-free survival (DFS) after curative resection (RO) of patients with TNM stage II gallbladder (GB) cancer. METHODS: A total of 160 patients who had received curative resection (RO) between January 2000 and December 2009 were retrospectively reviewed. Among 61 stage II GB cancer patients, 43 received adjuvant therapy, while 18 others received surgery alone. The median follow-up period was 27.3 months (range 2.2-98.9 months). RESULTS: OS was not significantly different among the adjuvant therapies (p = 0.180), but DFS was (p = 0.033). The 3-year OS and DFS from surgery alone, adjuvant chemotherapy, adjuvant radiotherapy, and adjuvant concurrent chemo-radiotherapy were 64, 78, 36 and 36%, and 56, 69, 14 and 47%, respectively. Overall, the chemotherapy group had a better prognosis, although there were no significant differences. CONCLUSIONS: The data from this study do not provide evidence that adjuvant therapy is an effective treatment option for curative resected GB cancer. A large randomized controlled study is necessary to confirm the efficacy of adjuvant therapy. Newer adjuvant studies should be focused on gemcitabine-based chemotherapy or chemo-radiotherapy with molecular-based target agents | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 168~173 | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/therapy* | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Adenosquamous/therapy* | - |
dc.subject.MESH | Carcinoma, Squamous Cell/therapy* | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Gallbladder Neoplasms/therapy* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Radiotherapy, Adjuvant | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Outcome of adjuvant therapy for gallbladder cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Park H.S. | - |
dc.contributor.googleauthor | Lim J.Y. | - |
dc.contributor.googleauthor | Yoon D.S. | - |
dc.contributor.googleauthor | Park J.S. | - |
dc.contributor.googleauthor | Lee D.K. | - |
dc.contributor.googleauthor | Lee S.J. | - |
dc.contributor.googleauthor | Choi H.J. | - |
dc.contributor.googleauthor | Song S.Y. | - |
dc.contributor.googleauthor | Lee W.J. | - |
dc.contributor.googleauthor | Cho J.Y. | - |
dc.identifier.doi | 10.1159/000322914 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01672 | - |
dc.contributor.localId | A02035 | - |
dc.contributor.localId | A02548 | - |
dc.contributor.localId | A02723 | - |
dc.contributor.localId | A02882 | - |
dc.contributor.localId | A03398 | - |
dc.contributor.localId | A03899 | - |
dc.contributor.localId | A04219 | - |
dc.contributor.localId | A02993 | - |
dc.relation.journalcode | J02416 | - |
dc.identifier.eissn | 1423-0232 | - |
dc.identifier.pmid | 21212704 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/322914 | - |
dc.subject.keyword | Adjuvant | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | Gallbladder carcinoma | - |
dc.subject.keyword | Radiotherapy | - |
dc.contributor.alternativeName | Park, Joon Seong | - |
dc.contributor.alternativeName | Song, Si Young | - |
dc.contributor.alternativeName | Yoon, Dong Sup | - |
dc.contributor.alternativeName | Lee, Dong Ki | - |
dc.contributor.alternativeName | Lee, Se Joon | - |
dc.contributor.alternativeName | Lee, Woo Jung | - |
dc.contributor.alternativeName | Lim, Jae Yun | - |
dc.contributor.alternativeName | Cho, Jae Yong | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | Park, Joon Seong | - |
dc.contributor.affiliatedAuthor | Song, Si Young | - |
dc.contributor.affiliatedAuthor | Yoon, Dong Sup | - |
dc.contributor.affiliatedAuthor | Lee, Dong Ki | - |
dc.contributor.affiliatedAuthor | Lee, Se Joon | - |
dc.contributor.affiliatedAuthor | Lim, Jae Yun | - |
dc.contributor.affiliatedAuthor | Cho, Jae Yong | - |
dc.contributor.affiliatedAuthor | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | Lee, Woo Jung | - |
dc.citation.volume | 79 | - |
dc.citation.number | 3-4 | - |
dc.citation.startPage | 168 | - |
dc.citation.endPage | 173 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, Vol.79(3-4) : 168-173, 2010 | - |
dc.identifier.rimsid | 56453 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.